Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Smile T1D semaglutide add-on trial in young people with type 1 diabetes
ISRCTN29694121Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 3, randomised, open-label trial in diabetes mellitus type 1 (T1D) comparing Semaglutide plus insulin standard of care with Insulin standard of care (2 arms). Primary endpoint: HbA1c at 26 weeks. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ISRCTN29694121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN29694121.